Savara Appoints David L. Lowrance As CFO

Published: Nov 02, 2016

AUSTIN, Texas, Nov. 2, 2016 /PRNewswire/ -- Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced the company has appointed David L. Lowrance, CPA, as its chief financial officer. Mr. Lowrance brings 25 years of private and public sector experience along with a successful record of executing IPOs to Savara, with the last 15 years of his career focused on the healthcare/biotech sector.

Prior to joining Savara, Mr. Lowrance served at the CFO for Edgemont Pharmaceuticals, a specialty pharmaceutical company focused on CNS drugs. Prior to Edgemont, he served as the CFO and Secretary of Acucela Inc., a clinical-stage biotechnology company, where he led a $162 million international IPO. From 2003 to 2011, Mr. Lowrance was vice president and CFO of Cumberland Pharmaceuticals Inc. where he led a successful $85 million IPO with a listing on NASDAQ in 2009.

"David compliments our team with a strong track record and deep private and public company experience," said Rob Neville, Chairman & CEO, Savara Pharmaceuticals. "He will be invaluable as we focus on bringing our two late-stage orphan drugs to market. We are proud to have him on board."

About Savara Pharmaceuticals
Savara Pharmaceuticals is an emerging specialty pharmaceutical company focused on rare respiratory diseases. The company has two products in late stage clinical trials including AeroVanc the first dry powder inhaled antibiotic being developed for the treatment of persistent MRSA infection in people with cystic fibrosis (CF) and Molgradex a proprietary, nebulized formulation of recombinant human GM-CSF for the treatment of pulmonary alveolar proteinosis (PAP).

Visit www.savarapharma.com, www.aerovanc.com, www.pap.info to learn more, or find us on TwitterFacebook and LinkedIn.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/savara-pharmaceuticals-appoints-david-l-lowrance-as-cfo-300355478.html

SOURCE Savara Pharmaceuticals

Back to news